Lbp Am Sa Acquires 5,085 Shares of BioNTech SE (NASDAQ:BNTX)

LBP AM SA raised its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 252,918 shares of the company's stock after purchasing an additional 5,085 shares during the quarter. LBP AM SA owned approximately 0.11% of BioNTech worth $28,820,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. FMR LLC raised its stake in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after buying an additional 5,598,190 shares during the period. Fred Alger Management LLC bought a new position in BioNTech during the third quarter worth $59,485,000. Braidwell LP acquired a new position in BioNTech in the 3rd quarter valued at $29,425,000. abrdn plc raised its position in shares of BioNTech by 70.7% in the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after buying an additional 159,676 shares in the last quarter. Finally, Redmile Group LLC acquired a new position in BioNTech during the third quarter worth about $18,345,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 1.9 %

NASDAQ:BNTX traded down $1.90 during trading hours on Tuesday, reaching $98.96. The company had a trading volume of 626,730 shares, compared to its average volume of 792,119. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.72 billion, a price-to-earnings ratio of -47.12 and a beta of 0.30. The business's 50-day simple moving average is $115.11 and its two-hundred day simple moving average is $113.46.

Remove Ads

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the business posted $1.90 EPS. The firm's revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

Analysts Set New Price Targets

BNTX has been the subject of a number of research analyst reports. Citigroup began coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a "buy" rating and a $145.00 price objective for the company. Wells Fargo & Company started coverage on BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 target price for the company. Truist Financial assumed coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a research report on Tuesday, November 26th. Finally, BMO Capital Markets upped their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $143.73.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.